Several phase III studies have demonstrated that the use of first- or second-generation EGFR-tyrosine kinase inhibitors (TKI) could increase progression-free survival (PFS) compared to platinum-based chemotherapy in advanced NSCLC patients with EGFR mutations2–9, which makes EGFR-TKI the mainstay treatment strategy for this condition. This evidence concerns the gene EGFR and non-small cell lung carcinoma.